fall 2024 laboratory update

We are working to accomplish three experimental priorities leading to translation of our second generation of bacterially delivered anticancer immunotherapy into human clinical trials.

First, we are determining the optimal dosing of drugs that create space within tumors to be occupied by our genetically engineered bacteria. Second, we are testing various modes of production and secretion in our bacteria to maximize delivery of immune-stimulating proteins into tumors. Third, we are studying the molecular and cellular mechanisms underlying this therapy. The results of this third group of experiments will inform the choice of additional immunomodulator protein combinations to eliminate tumors and establish anticancer immune memory that guards against any relapse due to residual disease.

This research is being conducted utilizing our mouse colony that consists of three tumor models, including breast, bone and connective tissue solid tumor cancers. Aside from personnel costs, maintenance of our mouse colony is our second largest expense.

Thank you very much for the generous philanthropic contributions that allow this work to proceed.